We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Top Stock Reports for Berkshire Hathaway, Colgate & CME Group
Read MoreHide Full Article
Tuesday, June 5, 2018
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway (BRK.B - Free Report) , Colgate (CL - Free Report) and CME Group (CME - Free Report) . These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Buy-ranked Berkshire Hathaway’s shares have gained +14.9% in the last year, outperforming the Zacks Property and Casualty Insurance industry which increased +11.3% during the same period. The Zacks analyst thinks Berkshire’s inorganic growth story remains impressive with strategic acquisitions. A strong cash position allows it to make earnings-accretive bolt-on acquisitions.
Demand for utilities is expected to rise in the future and drive earnings growth. Continued insurance business growth also fuels increase in float. A sturdy capital level further adds an impetus to the company. The insurance business generates maximum return on equity but its exposure to catastrophe loss remains a concern.
Huge capital expenses due to railroad operations have also emerged as headwinds. Capital expenditures are estimated at $10 billion in 2018. Nonetheless, the stock has witnessed its 2018 and 2019 estimates move up in the last 30 days.
Shares of Colgate have lost -10% over the last three months, underperforming the Zacks Consumer Staples sector, which has declined -8.1% over the same period. Colgate has been popular with investors for its meet or beat earnings track record.
Continuing with this trend, the company delivered an earnings beat in first-quarter 2018, after three consecutive quarters of in line earnings. Results continue to be driven by sales growth and significant market share gains. Going forward, the company remains on track with brand building and productivity maximization initiatives. Consequently, it provided a robust outlook for 2018.
Further, the company is encouraged by the progress on Global Growth and Efficiency Program along with additional savings anticipated from the recent expansion of the program. However, the company’s margins continue to be strained by higher raw material and packaging costs. Moreover, Colgate expects the backdrop to remain challenging in 2018 due to uncertain global markets and slowing category growth worldwide.
CME Group’s shares have outperformed the Zacks Securities and Exchanges industry in the last six months, gaining +11.5% vs. +6%. The Zacks analyst thinks the company remains well-positioned for growth on a strong market position with diverse derivative product lines.
Efforts to expand and cross sell its core exchange-traded business via new product initiatives and global reach also support growth. It intends to exit its credit default swap clearing business by mid-2018 and focus on over-the-counter clearing services on interest rate swaps as well as foreign exchange. This will free up $650 million as clearing member capital.
Also, the buyout of Nex Group will help CME generate $200 million in run-rate cost synergies annually by the end of 2021. However, exposure to interest rate volatility and limited credit availability might hamper liquidity.
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trendsand Earnings Previewreports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Top Stock Reports for Berkshire Hathaway, Colgate & CME Group
Tuesday, June 5, 2018
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway (BRK.B - Free Report) , Colgate (CL - Free Report) and CME Group (CME - Free Report) . These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Buy-ranked Berkshire Hathaway’s shares have gained +14.9% in the last year, outperforming the Zacks Property and Casualty Insurance industry which increased +11.3% during the same period. The Zacks analyst thinks Berkshire’s inorganic growth story remains impressive with strategic acquisitions. A strong cash position allows it to make earnings-accretive bolt-on acquisitions.
Demand for utilities is expected to rise in the future and drive earnings growth. Continued insurance business growth also fuels increase in float. A sturdy capital level further adds an impetus to the company. The insurance business generates maximum return on equity but its exposure to catastrophe loss remains a concern.
Huge capital expenses due to railroad operations have also emerged as headwinds. Capital expenditures are estimated at $10 billion in 2018. Nonetheless, the stock has witnessed its 2018 and 2019 estimates move up in the last 30 days.
(You can read the full research report on Berkshire Hathaway here >>>).
Shares of Colgate have lost -10% over the last three months, underperforming the Zacks Consumer Staples sector, which has declined -8.1% over the same period. Colgate has been popular with investors for its meet or beat earnings track record.
Continuing with this trend, the company delivered an earnings beat in first-quarter 2018, after three consecutive quarters of in line earnings. Results continue to be driven by sales growth and significant market share gains. Going forward, the company remains on track with brand building and productivity maximization initiatives. Consequently, it provided a robust outlook for 2018.
Further, the company is encouraged by the progress on Global Growth and Efficiency Program along with additional savings anticipated from the recent expansion of the program. However, the company’s margins continue to be strained by higher raw material and packaging costs. Moreover, Colgate expects the backdrop to remain challenging in 2018 due to uncertain global markets and slowing category growth worldwide.
(You can read the full research report on Colgate here >>>).
CME Group’s shares have outperformed the Zacks Securities and Exchanges industry in the last six months, gaining +11.5% vs. +6%. The Zacks analyst thinks the company remains well-positioned for growth on a strong market position with diverse derivative product lines.
Efforts to expand and cross sell its core exchange-traded business via new product initiatives and global reach also support growth. It intends to exit its credit default swap clearing business by mid-2018 and focus on over-the-counter clearing services on interest rate swaps as well as foreign exchange. This will free up $650 million as clearing member capital.
Also, the buyout of Nex Group will help CME generate $200 million in run-rate cost synergies annually by the end of 2021. However, exposure to interest rate volatility and limited credit availability might hamper liquidity.
(You can read the full research report on CME Group here >>>).
Other noteworthy reports we are featuring today include Tesla (TSLA - Free Report) , PPL Corporation (PPL - Free Report) and lululemon (LULU - Free Report) .
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Mark Vickery
Senior Editor
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>